Overview

• AstraZeneca plans to replace its US American Depositary Receipts on Nasdaq with a direct listing of ordinary shares on the New York Stock Exchange.
• The company says it will remain headquartered and tax resident in the UK and continue to be included in the FTSE 100 and OMX Stockholm 30 indices.
• The board published a circular and set a general meeting for Nov. 3, 2025, where investors will decide on the proposal.
• If approved, several reports indicate NYSE trading could begin in early 2026, with one outlet citing Feb. 2, 2026.
• Shares rose roughly 0.7% to 1.2% after the announcement, and some analysts called the move a setback for London that could stoke concerns about a future primary-listing shift.